Inimmune is a fast-moving innovative biotechnology company focused on the discovery and development of novel immunotherapeutics for allergy, autoimmunity, and cancer. Inimmune has a deep pipeline of early and late pre-clinical assets and a strong intellectual property position poised to change the landscape of immunotherapy. The Inimmune team of industry professionals has an average of >15 years of biotech/pharmaceutical experience and a long track record of success in bringing new vaccine adjuvants and immunotherapeutics to the marketplace. The Inimmune management team is actively seeking partnerships and investors who share our vision to create and develop new safe and effective immunotherapeutics for the treatment of allergy, autoimmunity, and cancer.
Research Contracts and Collaborators
Inimmune partners with some of the nation’s top universities and corporations in the field of immunology research. These are some of our current and previous collaborators.
In July 2020, Missoula-based biotech therapeutics company Inimmune announced the largest Series A investment in Montana history: a $22 million round led by Two Bear Capital out of Whitefish.
Two Bear Capital is led by Mike Goguen, a 20-year veteran of Sequoia Capital and based in Whitefish, MT. Goguen commented “The team at Inimmune combines world-class immunology and vaccine expertise, proven track records and a passion for solving some of the most important medical crises of our time.”